SUBSCRIBE
SUBSCRIBE

Vertex Pharmaceuticals

NEWS
Policy
Drug Giants Like Biogen, Vertex to Ignore Investor Calls to Explain Price Hikes
March 2, 2017
 · 
1 min read
Job Trends
Vertex’s Headcount Hits a New Four-Year High in 2016
February 24, 2017
 · 
1 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Business
Earnings Preview: Here’s a Look at What to Expect From 7 Biopharmas
January 23, 2017
 · 
3 min read
Genetown
Why Vertex Stock Sank 42% In 2016
January 17, 2017
 · 
1 min read
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse
Deals
JPM17: Vertex Game Plan for Growth in 2017
January 10, 2017
 · 
3 min read
Genetown
Mom To Vertex -"We’re Middle Class And We’re Screwed”
October 28, 2016
 · 
1 min read
Business
What to Look Out for When Biogen, Vertex Report Q3 This Week
October 24, 2016
 · 
1 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
After Hep C Flop, Has Vertex Learned From Its Past Mistakes?
October 18, 2016
 · 
3 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Genetown
Drug Pricing Woes Hit Vertex as One Mom Travels to Boston to Take on CEO
October 11, 2016
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
FDA
Vertex Receives EU Approval For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation
November 20, 2015
 · 
7 min read
FDA
Vertex Receives Two EU Approvals For KALYDECO (ivacaftor) For People With Cystic Fibrosis
November 18, 2015
 · 
6 min read
Genetown
Vertex To Present At The Credit Suisse Healthcare Conference On November 10
November 5, 2015
 · 
1 min read
Drug Development
Vertex Reports Third Quarter 2015 Financial Results
October 29, 2015
 · 
1 min read
Business
Vertex To Announce Third Quarter 2015 Financial Results On October 28
October 9, 2015
 · 
1 min read
Policy
Vertex Release: Supplemental New Drug Application For Use Of KALYDECO (Ivacaftor) In People With Cystic Fibrosis Ages 2 And Older Who Have One Of 23 Residual Function Mutations Accepted For Priority Review By FDA
October 8, 2015
 · 
9 min read
Drug Development
Vertex Announces Significant Progress In Its Development Efforts To Treat The Cause Of Cystic Fibrosis In The Vast Majority Of People With The Disease
October 8, 2015
 · 
20 min read
Vertex Receives CHMP Positive Opinions For ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) In The European Union
September 25, 2015
 · 
5 min read
Genetown
Vertex To Present At The Morgan Stanley Healthcare Conference On September 16
September 9, 2015
 · 
1 min read
Genetown
Vertex Awards Two Boston Public High School Students The Vertex Science Leaders Scholarship To The University Of Massachusetts
August 20, 2015
 · 
1 min read
Load More